The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
Open Access
- 6 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Vaccines
- Vol. 5 (1), 1-3
- https://doi.org/10.1038/s41541-020-0170-0
Abstract
The outbreak of 2019-novel coronavirus disease (COVID-19) that is caused by SARS-CoV-2 has spread rapidly in China, and has developed to be a Public Health Emergency of International Concern. However, no specific antiviral treatments or vaccines are available yet. This work aims to share strategies and candidate antigens to develop safe and effective vaccines against SARS-CoV-2.Keywords
This publication has 27 references indexed in Scilit:
- Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assayMethods, 2015
- Severe Acute Respiratory Syndrome Coronaviruses with Mutations in the E Protein Are Attenuated and Promising Vaccine CandidatesJournal of Virology, 2015
- A decade after SARS: strategies for controlling emerging coronavirusesNature Reviews Microbiology, 2013
- SARS vaccines: where are we?Expert Review of Vaccines, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunizationMolecular Immunology, 2006
- SARS Vaccine DevelopmentEmerging Infectious Diseases, 2005
- Mucosal immunisation of African green monkeys ( Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARSThe Lancet, 2004
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004
- A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adultsJournal of Viral Hepatitis, 1998